Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Valeo Pharma Inc. (C:VPH)

Business Focus: Pharmaceuticals (NEC)

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEDAR
Company Contact
Address: 16667 Hymus Blvd
Tel: N/A
IR: See website
Key People
Richard J. MacKay
Chairman of the Board
Jeff Skinner
Vice President - Business Development
Frederic Fasano
President, Chief Operating Officer, Director
Steven Saviuk
Chief Executive Officer, Director
Luc Mainville
Chief Financial Officer, Senior Vice President
Nelly Komari
Senior Vice President - Scientific and Medical Affairs
Helen Saviuk
Vice President - Operations
Michelle Brien
Vice President - Human Resources and Talent Management
Guy Paul Allard
Vice President - Legal Affairs, Corporate Secretary
Nathalie Therrien
Vice President - Quality Assurance and Regulatory Affairs
Business Overview
Valeo Pharma Inc. is a Canada-based specialty pharmaceutical company. The Company acquires or in-licenses brand and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology, specialty products, hospital generic division. Its respiratory/allergy products include Enerzair, Breezhaler, Atectura, Breezhaler and Allerject. Its ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis, Hesperco and Ametop Gel 4%. Its hospital generic division includes Benztropine, Ethacrynate Sodium and Amikacin. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.
Financial Overview
For the nine months ended 31 July 2022, Valeo Pharma Inc revenues increased 48% to C$15.1M. Net loss increased from C$6.6M to C$15.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Labor & Related Expenses in increase from C$2.6M to C$7.2M (expense), Interest on debentures increase from C$492K to C$2.3M (expense).
Employees: 100 as of Jul 31, 2022
Reporting Currency: Canadian Dollars
Enterprise value: $57.71M as of Oct 31, 2022
Annual revenue (TTM): $18.46M as of Oct 31, 2022
EBITDA (TTM): -$18.16M as of Oct 31, 2022
Net annual income (TTM): -$23.37M as of Oct 31, 2022
Free cash flow (TTM): -$32.93M as of Oct 31, 2022
Net Debt Last Fiscal Year: $30.23M as of Oct 31, 2022
Shares outstanding: 82,209,098 as of Jan 5, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization